Novartis has been active in the contract manufacturing space for twenty years, now under the brand name Global Biotech Cooperations.
Global Biotech Cooperations provides contract manufacturing services across various domains, including Cell & Gene Therapy, Plasmid DNA, RNA, mRNA, SiRNA, Microbial manufacturing, Mammalian cell cultures, Viral vector, and Fill & Finish.
Ahead of CPHI Barcelona 2023 Rathish Ravindrakumar, Business Development Director, Novartis Global Biotech Cooperations, explains how in the last 2-3 years they have been receiving more requests for newer technologies like Cell and Gene Therapy.
“These technologies represent both an opportunity and a challenge for some companies to get the required capacity. We can help these companies to manufacture their medicines as we have built our capabilities in these technologies.”
Sustainability is high on the Novartis agenda. Rathish highlights how the harmful effects of climate change are now clear to see, and will requires immediate and sustained action by all stakeholders.
“Sustainability has become the key issue for all contract manufacturers as pharma companies take proactive steps to deliver value chain emission reductions.”
“One of Novartis’ business objectives is building the green operations of the future” says Rathish “If you look at recently published analysis, Novartis is already ranked highly for its efforts to reduce greenhouse gas emissions.”
As an example of the work Novartis is undertaking, the company recently transitioned to 100% renewable energy in one of its large-scale sites. This is part of a group-wide sustainability journey to be carbon neutral across its own operations by 2025 and across its supply chain by 2030.
Meet Novartis Global Biotech Cooperations at their stand 3F68 or visit their website.
Stay ahead of trends and best practices
